The United Laboratories International Holdings (ULIHF) Price & Analysis

Compare

20 Followers

ULIHF Stock Chart & Stats

$1.88

$0.10(8.70%)

At close: Oct 18 4:00 PM EDT

$1.88

$0.10(8.70%)

Day’s Range― - ―

52-Week Range$1.43 - $2.45

Previous CloseN/A

Volume13.00K

Average Volume (3M)0.00

Market Cap

$3.22B

Enterprise Value$18.38B

Total Cash (Recent Filing)$9.01B

Total Debt (Recent Filing)$5.13B

Price to Earnings (P/E)8.0

Beta-0.43

Next Earnings

Mar 31, 2026

EPS Estimate

0.03

Next Dividend Ex-DateN/A

Dividend Yield2.82%

Share Statistics

EPS (TTM)0.15

Shares Outstanding1,973,026,500

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-3.94

Price to Book (P/B)1.47

Price to Sales (P/S)1.53

P/FCF Ratio15.87

Enterprise Value/Market Cap5.71

Enterprise Value/Revenue1.30

Enterprise Value/Gross Profit2.76

Enterprise Value/Ebitda4.74

Forecast

1Y Price Target

$2.28

Price Target Upside21.23% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cost ManagementSelling costs were reduced by Rmb260mn to Rmb715mn, showing a significant year-over-year decrease.

Growth ProjectionsFurther growth is expected from finished drugs, including the soon-to-be-approved liraglutide generic, insulins, and animal drugs.

Product LaunchesAnimal drugs are on a strong growth track with new product launches.

Bears Say

Capacity ConcernsManagement does not see extra capacity coming online to pressure 6-APA prices, which might limit future supply flexibility.

Market ExpectationsStreet's estimate has already moved up by 6% since early July, suggesting expectations may be high and challenging to exceed.

Profit Outlook1H24 net profit was in line with estimates, but only slightly above consensus, indicating limited upside surprise.

The United Laboratories International Holdings News

United Laboratories’ Roxithromycin Capsules Gain First-in-China Consistency Approval

The latest announcement is out from The United Laboratories International Holdings ( ($HK:3933) ). The United Laboratories International...

3d ago

United Laboratories Wins China Trial Nod for First-in-China Triple Agonist UBT251 in Obstructive Sleep Apnea

The United Laboratories International Holdings ( ($HK:3933) ) just unveiled an announcement. The United Laboratories International Holdings has...

9d ago

United Laboratories Wins U.S. FDA IND Approval for Novel Anti-Infective TUL108

The United Laboratories International Holdings ( ($HK:3933) ) has issued an update. The United Laboratories International Holdings has...

15d ago

United Laboratories Gains Approval for Levofloxacin Eye Drops

The United Laboratories International Holdings ( ($HK:3933) ) has provided an update. The United Laboratories International Holdings Limited...

2M ago

United Laboratories’ Moxifloxacin Eye Drops Gain Approval, Boosting Ophthalmic Portfolio

The United Laboratories International Holdings ( ($HK:3933) ) has issued an announcement. The United Laboratories International Holdings Limited...

2M ago

United Laboratories’ Antibiotic Product Passes Consistency Evaluation

An update from The United Laboratories International Holdings ( ($HK:3933) ) is now available. The United Laboratories International...

3M ago

United Laboratories Announces Vesting of Award Shares

The United Laboratories International Holdings ( ($HK:3933) ) just unveiled an announcement. The United Laboratories International Holdings Limited...

3M ago

United Laboratories Advances TUL01101 Tablets to Phase III Trials

The United Laboratories International Holdings ( ($HK:3933) ) has issued an announcement. The United Laboratories International Holdings Limited...

3M ago

United Laboratories Acquires Award Shares for Share Scheme

The latest announcement is out from The United Laboratories International Holdings ( ($HK:3933) ). The United Laboratories International...

3M ago

The United Laboratories Announces 2025 Interim Dividend Payment

The United Laboratories International Holdings ( ($HK:3933) ) has issued an update. The United Laboratories International Holdings Limited...

4M ago

ULIHF FAQ

What was The United Laboratories International Holdings Limited’s price range in the past 12 months?

The United Laboratories International Holdings Limited lowest stock price was $1.43 and its highest was $2.45 in the past 12 months.

What is The United Laboratories International Holdings Limited’s market cap?

The United Laboratories International Holdings Limited’s market cap is $3.22B.

When is The United Laboratories International Holdings Limited’s upcoming earnings report date?

The United Laboratories International Holdings Limited’s upcoming earnings report date is Mar 31, 2026 which is in 47 days.

How were The United Laboratories International Holdings Limited’s earnings last quarter?

The United Laboratories International Holdings Limited released its earnings results on Aug 28, 2025. The company reported $0.151 earnings per share for the quarter, missing the consensus estimate of $0.192 by -$0.042.

Is The United Laboratories International Holdings Limited overvalued?

According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does The United Laboratories International Holdings Limited pay dividends?

The United Laboratories International Holdings Limited pays a Quarterly dividend of $0.022 which represents an annual dividend yield of 2.82%. See more information on The United Laboratories International Holdings Limited dividends here

What is The United Laboratories International Holdings Limited’s EPS estimate?

The United Laboratories International Holdings Limited’s EPS estimate is 0.03.

How many shares outstanding does The United Laboratories International Holdings Limited have?

The United Laboratories International Holdings Limited has 1,973,026,500 shares outstanding.

What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?

The United Laboratories International Holdings Limited reported an EPS of $0.151 in its last earnings report, missing expectations of $0.192. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?

Currently, no hedge funds are holding shares in ULIHF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

The United Laboratories International Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

21.02%

Trailing 12-Months

Asset Growth

30.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

The United Laboratories International Holdings Limited

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.

The United Laboratories International Holdings (ULIHF) Earnings & Revenues

Historic Earnings Reports

ULIHF Stock 12 Month Forecast

Average Price Target

$2.28

▲(21.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.2790586000000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.2790586000000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.2790586000000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.875,1.9060814307692309,1.9371628615384615,1.9682442923076924,1.9993257230769232,2.030407153846154,2.0614885846153848,2.0925700153846156,2.1236514461538465,2.1547328769230774,2.185814307692308,2.2168957384615386,2.2479771692307695,{"y":2.2790586000000004,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.875,1.9060814307692309,1.9371628615384615,1.9682442923076924,1.9993257230769232,2.030407153846154,2.0614885846153848,2.0925700153846156,2.1236514461538465,2.1547328769230774,2.185814307692308,2.2168957384615386,2.2479771692307695,{"y":2.2790586000000004,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.875,1.9060814307692309,1.9371628615384615,1.9682442923076924,1.9993257230769232,2.030407153846154,2.0614885846153848,2.0925700153846156,2.1236514461538465,2.1547328769230774,2.185814307692308,2.2168957384615386,2.2479771692307695,{"y":2.2790586000000004,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.973,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.018,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.079,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.079,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.246,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.529,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.366,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.366,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.773,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.621,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.621,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.875,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >